Alzamend Neuro Gets 'Study May Proceed' Letter for Phase I/IIA Trial for Vaccine for Dementia of Alzheimer’s Type

 Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease ("Alzheimer’s"), bipolar disorder, major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug Administration ("FDA") for a phase I/IIA clinical trial under its Investigational New Drug ("IND") application for an immunotherapy (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type.

https://finance.yahoo.com/news/alzamend-neuro-receives-fda-study-120000263.html